multipl
pharmacolog
intervent
test
last
decad
fail
reduc
ard
mortal
short
note
recount
past
data
indic
neutrophil
home
along
gradient
ii
ard
massiv
neutrophil
accumul
degranul
along
bronchoalveolar
space
contribut
damag
hypoxia
iii
larg
increas
one
chemotax
signal
draw
neutrophil
ard
lung
iv
old
data
dermatolog
glioblastoma
research
show
old
drug
hansen
diseas
dapson
inhibit
neutrophil
chemotaxi
therefor
dapson
might
lower
neutrophil
contribut
ard
lung
patholog
dapson
creat
methemoglobinemia
although
rare
problemat
would
particularli
undesir
ard
common
antacid
drug
cimetidin
lower
risk
dapson
relat
methemoglobinemia
given
concomitantli
articl
histori
acut
respiratori
distress
syndrom
ard
continu
high
lethal
short
note
recount
past
data
show
attract
neutrophil
increas
ard
bring
neutrophil
lung
neutrophil
degranul
contribut
alveolar
damag
characterist
ard
regardless
initi
event
trigger
ard
dapson
use
year
antibiot
unrel
attribut
antibiot
dapson
use
year
treat
varieti
neutrophil
dermatos
dermat
herpetiformi
bullou
pemphigoid
et
al
rheumatoid
arthriti
neutrophil
dermatos
dapson
work
inhibit
mediat
neutrophil
chemotaxi
lead
amelior
diseas
without
effect
underli
patholog
observ
lead
conclus
dapson
might
amelior
ardsrel
lung
tissu
destruct
improv
outcom
reduc
neutrophil
contribut
without
effect
underli
diseas
trigger
ard
ard
sever
form
acut
lung
injuri
character
acut
diffus
bilater
pulmonari
infiltr
neutrophil
monocyt
lymphocyt
diminish
lung
complianc
alveolar
destruct
bronchoalveolar
lumen
hyalin
deposit
lead
hypoxem
respiratori
failur
though
mani
trigger
precipit
event
lead
ard
f
ex
crush
injuri
pneumonia
origin
includ
corona
viru
sepsi
result
pathophysiolog
degre
stereotyp
diffus
alveolar
damag
one
characterist
defin
featur
acut
phase
ard
diffus
alveolar
damag
character
edema
hyalin
deposit
dens
leukocyt
infiltr
day
follow
organ
phase
septal
fibrosi
pneumocyt
hyperplasia
clinic
consequ
seri
event
hypoxemia
multiorgan
failur
high
death
rate
ard
go
develop
diffus
alveolar
damag
higher
case
fatal
rate
crucial
intend
use
dapson
baughman
et
al
document
compar
studi
bronchoalveolar
lavag
earli
second
lavag
late
ard
reduct
neutrophil
second
lavag
predict
surviv
nonreduct
predict
death
ard
neutrophil
show
activ
marker
excess
transendotheli
migrat
cytokineprim
neutrophil
consist
directli
correl
degre
neutrophil
concentr
ard
lung
among
immuneinflammatori
cell
infiltr
degranul
neutrophil
pivot
develop
capillari
damag
subsequ
leakag
hyalin
deposit
ard
transit
deadli
diffus
alveolar
damag
phase
antibodi
inhibit
develop
ard
sever
differ
ard
anim
model
level
neutrophil
accumul
directli
correl
ard
sever
pivot
neutrophil
contribut
hope
diminish
dapson
neutrophil
degranul
releas
intracellular
enzym
neutrophil
elastas
oxid
product
particip
alveolardestruct
process
ard
neutrophil
migrat
along
sever
chemokin
gradient
along
gradient
elev
human
bronchoalveolar
lavag
fluid
ard
higher
lavag
concentr
correl
higher
diffus
alveolar
damag
mortal
also
higher
lavag
fluid
correl
higher
neutrophil
infiltr
high
circul
characterist
ard
act
alon
attract
neutrophil
lung
act
part
suit
chemokin
albeit
central
pivot
role
dapson
long
histori
use
treat
neutrophil
dermatos
rheumatoid
arthriti
use
nonantibiot
role
use
led
discoveri
dapson
amelior
dermatos
primarili
inhibit
neutrophil
migrat
along
gradient
proof
characterist
rash
caus
erlotinib
mediat
turn
led
dapson
use
treat
neutrophil
rash
vitro
studi
show
dapson
inhibit
neutrophil
chemotaxi
nformylmethionylleucylphenylalanin
via
interfer
neutrophil
adher
function
altogeth
observ
turn
led
current
suggest
dapson
treatment
adjunct
ard
neutrophil
infiltr
alveoli
present
ard
relat
coronaviru
infect
cov
sarscov
middl
east
respiratori
syndrom
cov
merscov
probabl
unproven
also
true
relat
ard
dapson
sulfon
antibiot
use
sinc
treat
mycobacteri
diseas
infect
includ
pneumocysti
plasmodia
other
list
essenti
medicin
virtu
dapson
abil
inhibit
neutrophil
chemotaxi
site
inflamm
dapson
seen
wide
dermatolog
use
treat
neutrophil
dermatos
vitro
model
martin
et
al
demonstr
activ
neutrophil
damag
pulmonari
endothelium
significantli
inhibit
dapson
furthermor
demonstr
effect
mediat
dapson
inhibit
neutrophil
respiratori
burst
mg
oral
dapson
serum
concentr
mgl
seen
h
halflif
vari
h
usual
dose
higher
end
would
mg
q
h
histamin
receptor
block
drug
cimetidin
mg
everi
h
mg
everi
h
improv
therapeut
index
reduc
dapson
nhydroxyl
nhydroxyl
dapson
monohydroxylamin
primarili
respons
dapson
relat
methemoglobinemia
slight
methemoglobinemia
common
sever
methemoglobinemia
common
rare
dapson
relat
hypersensit
seen
associ
lung
injuri
dapson
work
intend
question
remain
start
earli
risk
treat
peopl
unnecessarili
late
damag
alreadi
done
given
sever
current
worldwid
crisi
earli
upon
diagnosi
symptom
might
best
research
inde
show
dapson
mitig
ard
sever
cimetidin
given
dapson
methemoglobinemia
must
frequent
check
dapson
tri
given
high
mortal
ard
rel
benign
natur
dapson
cimetidin
trial
dapson
mg
everi
h
plu
cimetidin
mg
everi
h
seem
warrant
thank
colleagu
marcer
halatsch
georg
karpelmassl
tim
le
clair
eric
l
altschul
encourag
help
discuss
flaw
paper
mine
author
conflict
interest
declar
unfund
research
